Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1ZQ5G)

• Drug Name: (S)-Xamoterol Drug Info
• Synonyms: UNII-ZIB581LRDV; ZIB581LRDV; (S)-Xamoterol; Xamoterol, (S)-; 69630-22-4; SCHEMBL11533496; ZINC1532365; UNII-7HE0JQL703 component DXPOSRCHIDYWHW-AWEZNQCLSA-N; 4-Morpholinecarboxamide, N-(2-(((2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-
• Cross-matching ID:
  PubChem CID: 12681891
  CAS Number: CAS 69630-22-4
  TTD Drug ID: DM1ZQ5G
  VARIDT Drug ID: DR01671

Molecule-Related Drug Atlas

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[2]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[3]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[5]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[6]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[7]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[8]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[9]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[10]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[1]

References

• [1] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [2] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [3] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [4] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [5] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [6] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [7] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [8] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [9] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [10] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [11] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.